ReviewFrontiers in oncology2023

Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings.

Fang Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.